vs
Side-by-side financial comparison of GOLDEN HEAVEN GROUP HOLDINGS LTD. (GDHG) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
GOLDEN HEAVEN GROUP HOLDINGS LTD. is the larger business by last-quarter revenue ($15.3M vs $9.1M, roughly 1.7× Protalix BioTherapeutics, Inc.). GOLDEN HEAVEN GROUP HOLDINGS LTD. runs the higher net margin — -56.2% vs -60.3%, a 4.1% gap on every dollar of revenue.
Golden Heaven Group Holdings Ltd. operates large-scale amusement parks, cultural tourism complexes and family-focused leisure venues primarily across mainland China. Its core services include thrill rides, themed entertainment zones, cultural experience activities, plus supporting catering and retail offerings, catering to leisure demands of consumers across all age groups.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
GDHG vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.3M | $9.1M |
| Net Profit | $-8.6M | $-5.5M |
| Gross Margin | 50.2% | 49.4% |
| Operating Margin | -44.5% | -51.1% |
| Net Margin | -56.2% | -60.3% |
| Revenue YoY | — | -49.9% |
| Net Profit YoY | — | -184.8% |
| EPS (diluted) | $-10.83 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $9.1M | ||
| Q3 25 | $15.3M | $17.9M | ||
| Q2 25 | — | $15.7M | ||
| Q1 25 | $13.8M | $10.1M | ||
| Q4 24 | — | $18.2M | ||
| Q3 24 | — | $18.0M | ||
| Q2 24 | — | $13.5M | ||
| Q1 24 | $13.8M | — |
| Q4 25 | — | $-5.5M | ||
| Q3 25 | $-8.6M | $2.4M | ||
| Q2 25 | — | $164.0K | ||
| Q1 25 | — | $-3.6M | ||
| Q4 24 | — | $6.5M | ||
| Q3 24 | — | $3.2M | ||
| Q2 24 | — | $-2.2M | ||
| Q1 24 | $2.5M | — |
| Q4 25 | — | 49.4% | ||
| Q3 25 | 50.2% | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | 52.0% | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | 52.0% | — |
| Q4 25 | — | -51.1% | ||
| Q3 25 | -44.5% | 11.9% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | -41.0% | ||
| Q4 24 | — | 39.6% | ||
| Q3 24 | — | 22.2% | ||
| Q2 24 | — | -18.0% | ||
| Q1 24 | 25.5% | — |
| Q4 25 | — | -60.3% | ||
| Q3 25 | -56.2% | 13.2% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | -35.8% | ||
| Q4 24 | — | 35.6% | ||
| Q3 24 | — | 18.0% | ||
| Q2 24 | — | -16.4% | ||
| Q1 24 | 18.4% | — |
| Q4 25 | — | $-0.06 | ||
| Q3 25 | $-10.83 | $0.03 | ||
| Q2 25 | — | $0.00 | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $0.03 | ||
| Q2 24 | — | $-0.03 | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $86.0M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $180.7M | $48.2M |
| Total Assets | $191.4M | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $14.7M | ||
| Q3 25 | $86.0M | $13.6M | ||
| Q2 25 | — | $17.9M | ||
| Q1 25 | $19.8M | $19.5M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | — | $27.4M | ||
| Q2 24 | — | $23.4M | ||
| Q1 24 | $129.4K | — |
| Q4 25 | — | $48.2M | ||
| Q3 25 | $180.7M | $52.9M | ||
| Q2 25 | — | $49.9M | ||
| Q1 25 | $83.7M | $45.2M | ||
| Q4 24 | — | $43.2M | ||
| Q3 24 | — | $32.4M | ||
| Q2 24 | — | $28.6M | ||
| Q1 24 | $64.3M | — |
| Q4 25 | — | $82.3M | ||
| Q3 25 | $191.4M | $82.3M | ||
| Q2 25 | — | $78.5M | ||
| Q1 25 | $98.6M | $73.9M | ||
| Q4 24 | — | $73.4M | ||
| Q3 24 | — | $61.6M | ||
| Q2 24 | — | $91.5M | ||
| Q1 24 | $82.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $19.0M | $2.0M |
| Free Cash FlowOCF − Capex | — | $1.6M |
| FCF MarginFCF / Revenue | — | 17.8% |
| Capex IntensityCapex / Revenue | — | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.0M | ||
| Q3 25 | $19.0M | $-3.7M | ||
| Q2 25 | — | $-5.2M | ||
| Q1 25 | — | $-5.1M | ||
| Q4 24 | — | $4.0M | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | — | $-3.6M | ||
| Q1 24 | $-911.6K | — |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q1 24 | $-924.9K | — |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q1 24 | -6.7% | — |
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.36× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GDHG
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
